NFE2L2 and non-small cell lung carcinoma: Our study raises the possibility that a deeper understanding of CsA’s mechanism will inspire a more reasonable therapeutic regimen in future clinical investigations using new, optimized PPIA inhibitors to treat patients with NRF2-hyperactivated NSCLC.